NephroNET

We are dedicated to providing resources to patients, practicing clinicians, and all individuals concerned w/ improving the care of patients with kidney disease.

[NephroNET @NephroNet]

Life is all about balance — just ask your nephrons.

[NephroNET @NephroNet]

Insight of the Week - Kidney care is evolving—new IgA nephropathy targets, advanced diagnostics like mNGS, and precision medicine are driving earlier detection & tailored treatments for better outcomes. Support research & advocate for kidney health. #Nephrology #Innovation

[NephroNET @NephroNet]

CHANCE-2 trial: In stroke pts w/ CYP2C19 LOF, ticagrelor cut stroke risk in both age groups w/ normal kidneys, but no benefit in mild impairment. #Stroke #Nephrology
https://t.co/BxZPKhgtC4

[NephroNET @NephroNet]

🥦 What’s your go-to kidney-friendly food or healthy snack?

[NephroNET @NephroNet]

United in remembrance. Stronger together.

[NephroNET @NephroNet]

Proof That No Summit Is Too High After Transplant
https://t.co/3FtTFkJuaW

[NephroNET @NephroNet]

Empowering Kidney Care, One Episode at a Time!
https://t.co/kb2M9DUzwn

[NephroNET @NephroNet]

Clinical Trials for Pig-to-Human Kidney Transplantation Are Here. From Research to Real-World Impact!
https://t.co/vNBG2h9Zkk

[NephroNET @NephroNet]

Multi-institutional study in pediatric lupus shows reliable capture of BP, proteinuria & RAAS inhibitor use across 6 sites. Findings reveal high hypertension/proteinuria rates, variation in treatment, & opportunities to standardize care. #PediatricLupus https://t.co/3PVdCiLIWW

[NephroNET @NephroNet]

💊 Breakthrough in Lupus Nephritis Treatment!

Results from the REGENCY phase 3 trial show that adding obinutuzumab to standard therapy significantly improved kidney outcomes in adults with active lupus nephritis. https://t.co/t5TTU3RyHD

[NephroNET @NephroNet]

A dual GLP-1 & glucagon receptor agonist, significantly reduced urinary albumin-to-creatinine ratio (UACR) in patients w/ type 2 diabetes & chronic kidney disease. At 14 weeks, reductions reached ~44% w/ 300 μg & ~50% with 600 μg versus placebo, w/ effects sustained at 26 weeks.

[NephroNET @NephroNet]

🌟 Nephrology is evolving—precision medicine, advanced therapies, AI, next-gen diagnostics & whole-patient wellness are transforming kidney care. The goal: longer, healthier lives & smarter decisions for patients. #Nephrology #KidneyHealth #Innovation #PatientCare

[NephroNET @NephroNet]

A Son’s Gift: How His Kidney Donation Saved Two Lives and Transformed His Own
https://t.co/LQW3Inzidr

[NephroNET @NephroNet]

🧪 Promising Results in IgA Nephropathy!
A phase 3 trial shows that atrasentan, a selective endothelin A receptor antagonist, significantly reduced proteinuria in patients with IgA nephropathy and high kidney risk.
#KidneyResearch 🔗 Learn more: https://t.co/BY6eGLu31t

[NephroNET @NephroNet]

2026 NephroNet Nephrology Update Conference #NephroNetLive #KidneyCare #HealthcareLeaders #ConnectLearnLead

[NephroNET @NephroNet]

2026 NephroNet Nephrology Update Conference #HealthcareInnovation #NephroNetUpdate #KidneyHealth #CollaborationInCare

[NephroNET @NephroNet]

Breakthrough in Lupus Nephritis Treatment! Results from the REGENCY phase 3 trial show that adding obinutuzumab to standard therapy significantly improved kidney outcomes in adults with active lupus nephritis. Read more: https://t.co/pu9IKk1ySl
#LupusNephritis #ClinicalTrials

[NephroNET @NephroNet]

Phase 3 APPEAR-C3G trial:
Iptacopan (LNP023) cut proteinuria by 35% vs placebo at 6 months in C3 glomerulopathy.
Well-tolerated with no meningococcal infections or treatment discontinuations.
#nephrology.
#C3G #ClinicalTrials #KidneyResearch
https://t.co/o1hDEsXpwt

[NephroNET @NephroNet]

2026 NephroNet Nephrology Update Conference #NephroNet #Nephrology #RenalCare #ClinicalResearch #Atlanta

[NephroNET @NephroNet]

MOC & CME CREDITS AVAILABLE! Advance Your Clinical Edge — Register Now!
https://t.co/6GR2ltaGz1